Literature DB >> 19753485

Perspectives of vaccination in Chagas disease revisited.

Erney Plessmann Camargo1.   

Abstract

The perspectives for a Chagas Disease vaccine 30 years ago and today are compared. Antigens and adjuvants have improved, but logistic problems remain the same. Sterilizing vaccines have not been produced and animal models for chronic Chagas have not been developed. Vector control has been successful and Chagas incidence has come to a halt. We do not have a population candidate to vaccination now in Brazil. And if we had, we would not know how to evaluate the success of vaccination in a short time period. A vaccine may not seem important at the moment. However, scientific reasons and incertitudes about the future recommend that a search for a vaccine be continued.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19753485     DOI: 10.1590/s0074-02762009000900036

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  9 in total

1.  Parasites and immunotherapy: with or against?

Authors:  Hossein Yousofi Darani; Morteza Yousefi; Marzieh Safari; Rasool Jafari
Journal:  J Parasit Dis       Date:  2014-08-31

Review 2.  Advances and challenges towards a vaccine against Chagas disease.

Authors:  Israel Quijano-Hernandez; Eric Dumonteil
Journal:  Hum Vaccin       Date:  2011-11-01

3.  "Manifesto" for advancing the control and elimination of neglected tropical diseases.

Authors:  Peter J Hotez; Bernard Pecoul
Journal:  PLoS Negl Trop Dis       Date:  2010-05-25

4.  Chagas disease risk in Texas.

Authors:  Sahotra Sarkar; Stavana E Strutz; David M Frank; Chissa-Louise Rivaldi; Blake Sissel; Victor Sánchez-Cordero
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

Review 5.  Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects.

Authors:  Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez; Bin Zhan; Michael J Heffernan; Kathryn Jones; Jesus G Valenzuela; Shaden Kamhawi; Jaime Ortega; Samuel Ponce de Leon Rosales; Bruce Y Lee; Kristina M Bacon; Bernhard Fleischer; B T Slingsby; Miguel Betancourt Cravioto; Roberto Tapia-Conyer
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

6.  Trypanosoma cruzi response to sterol biosynthesis inhibitors: morphophysiological alterations leading to cell death.

Authors:  Rafael Luis Kessler; Maurilio José Soares; Christian Macagnan Probst; Marco Aurélio Krieger
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

7.  Immune protection against Trypanosoma cruzi induced by TcVac4 in a canine model.

Authors:  José E Aparicio-Burgos; José A Zepeda-Escobar; Roberto Montes de Oca-Jimenez; José G Estrada-Franco; Alberto Barbabosa-Pliego; Laucel Ochoa-García; Ricardo Alejandre-Aguilar; Nancy Rivas; Giovanna Peñuelas-Rivas; Margarita Val-Arreola; Shivali Gupta; Felix Salazar-García; Nisha J Garg; Juan C Vázquez-Chagoyán
Journal:  PLoS Negl Trop Dis       Date:  2015-04-08

8.  Assessment of sesquiterpene lactones isolated from Mikania plants species for their potential efficacy against Trypanosoma cruzi and Leishmania sp.

Authors:  Laura C Laurella; Natacha Cerny; Augusto E Bivona; Andrés Sánchez Alberti; Gustavo Giberti; Emilio L Malchiodi; Virginia S Martino; Cesar A Catalan; María Rosario Alonso; Silvia I Cazorla; Valeria P Sülsen
Journal:  PLoS Negl Trop Dis       Date:  2017-09-25

9.  Vaccination of dogs with Trypanosoma rangeli induces antibodies against Trypanosoma cruzi in a rural area of Córdoba, Argentina.

Authors:  Beatriz Basso; Vanina Marini; Diego Gauna; Maria Frias
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-04       Impact factor: 2.743

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.